Page last updated: 2024-12-08

7-ketolithocholic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

7-ketolithocholic acid: RN given refers to (3alpha,5beta)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

7-oxolithocholic acid : A bile acid that is lithocholic acid carrying an additional oxo substituent at position 7. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID444262
CHEMBL ID1254169
CHEBI ID82679
SCHEMBL ID234771
MeSH IDM0079768

Synonyms (51)

Synonym
3.alpha.-hydroxy-7-oxo-5.beta.-cholanic acid
4651-67-6
LMST04010150
3alpha-hydroxy-7-oxo-5beta-cholan-24-oic acid
7-oxolithocholic acid
ccris 3987
3alpha-hydroxy-7-oxo-5beta-cholanic acid ,
cholan-24-oic acid, 3-hydroxy-7-oxo-, (3alpha,5beta)-
7-ketolithocholic acid
nsc 226118
(3alpha,5beta)-3-hydroxy-7-oxocholan-24-oic acid
einecs 225-083-2
3alpha-hydroxy-7-oxo-5beta-cholanoic acid
(4r)-4-[(3r,5s,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-7-oxo-1,2,3,4,5,6,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]pentanoic acid
H0869
3alpha-hydroxy-7-keto-5beta-cholanic acid
y1357h1a28 ,
unii-y1357h1a28
ec 225-083-2
CHEMBL1254169
chebi:82679 ,
AKOS016010910
AKOS015855480
cholan-24-oic acid, 3-hydroxy-7-oxo-, (3.alpha.,5.beta.)-
7-oxo-3.alpha.-hydroxycholan-24-oic acid
7-keto-lithocholic acid
3.alpha.-hydroxy-7-oxo-5.beta.-cholic acid
ursodeoxycholic acid impurity f [ep impurity]
3.alpha.-hydroxy-7-oxo-5.beta.-cholan-24-oic acid
3.alpha.-hydroxy-7-oxo-5.beta.-cholanoic acid
SCHEMBL234771
nutriacholic acid
3alpha-hydroxy-7-keto-5beta-cholan-24-oic acid
7-oxo-3alpha-hydroxycholan-24-oic acid
3a-hydroxy-7-oxo-5b-cholanic acid
cholan-24-oic acid, 3-hydroxy-7-oxo-, (3a,5b)-
CS-W019298
3-hydroxy-7-oxocholan-24-oic acid #
AC-29218
3i+/--hydroxy-7-oxo-5i(2)-cholanic acid
7-keto-lca
DS-4325
Q27156201
(3a,5ss)-3-hydroxy-7-oxo-cholan-24-?oic acid
AMY1798
st 24:2;o4
HY-W018512
F11720
3alpha--hydroxy-7-oxo-5beta-cholanic acid
PD131213
DTXSID501032263

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Finally, CDCA, DCA and LagoDCA were prominent outliers being more toxic than predicted by RMw."( Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).
Gilmer, JF; Keaveney, R; Kelleher, D; Long, A; Majer, F; Peta, VK; Sharma, R; Wang, J, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
bile acidAny member of a group of hydroxy-5beta-cholanic acids occuring in bile, where they are present as the sodium salts of their amides with glycine or taurine. In mammals bile acids almost invariably have 5beta-configuration.
monohydroxy-5beta-cholanic acid
oxo-5beta-cholanic acid
3alpha-hydroxy steroidA 3-hydroxy steroid in which the 3-hydroxy substituent is in the alpha-position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID515399Cytotoxicity against human HuH7 cells assessed as cell viability at 500 uM after 24 hrs by MTT assay relative to control2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).
AID515400Cytotoxicity against human HET-1A cells assessed as cell viability at 500 uM after 24 hrs by MTT assay relative to control2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).
AID515398Cytotoxicity against human HET-1A cells assessed as cell viability after 24 hrs by MTT assay2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (37)

TimeframeStudies, This Drug (%)All Drugs %
pre-199021 (56.76)18.7374
1990's6 (16.22)18.2507
2000's1 (2.70)29.6817
2010's8 (21.62)24.3611
2020's1 (2.70)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.55

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.55 (24.57)
Research Supply Index3.66 (2.92)
Research Growth Index4.88 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.55)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.63%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other37 (97.37%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]